Thursday, September 10, 2020 8:56:57 AM
Possibly, but I'm not ready to call that one :) Now that we know they're working on a manufacturing solution in the US, that could also mean they use the US as a template (FDA approval, manufacturing, and distribution models) to expand into other major markets, keeping Relief in tact. In that case, they would need a CEO and such. And/Or license out the rights to market the drug in each country to someone like Pfiser, J&J, or Eli (given their connections), which would also solve big pharma/political issues. We shall keep our ear to the ground.
(all speculation)
(all speculation)
Disclaimer: I am not a professional advisor. Seek professional advice before investing or trading. I take risky positions and do not advise anyone to follow my opinions or actions.
Recent RLFTF News
- MindMaze Therapeutics Announces Initiation of Coverage by Baader Bank • ACCESS Newswire • 03/19/2026 06:35:00 AM
- MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics • ACCESS Newswire • 12/23/2025 06:20:00 AM
- Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics • ACCESS Newswire • 12/15/2025 06:20:00 AM
- Relief Therapeutics Shareholders Approve Business Combination with NeuroX • ACCESS Newswire • 11/14/2025 05:40:00 PM
- Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032 • ACCESS Newswire • 10/29/2025 06:20:00 AM
